NCT01469598View on ClinicalTrials.gov

Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

January 31, 2015

Conditions
Metastatic CarcinomaRecurrent Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Gemcitabine/Docetaxel

Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days

Trial Locations (1)

Unknown

Samsung medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT01469598 - Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer | Biotech Hunter | Biotech Hunter